Report Detail
Global (United States, European Union and China) Hepatic Encephalopathy (HE) Therapeutics Market Research Report 2019-2025
- RnM3659561 |
- 09 August, 2019 |
- Global |
- 116 Pages |
- QYResearch |
- Pharma & Healthcare
HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.
The availability of patient-focused programs to assist disease management is one of the primary growth drivers for the global hepatic encephalopathy (HE) therapeutics market till 2023. Such programs increase the adherence to therapeutics by improving convenience for patients. Norgine collaborated with the European liver patients association (ELPA) to launch Time to DeLiver program, which is focused on changing the perception about HE among all stakeholders, healthcare professionals, and policymakers. This in turn, drives the demand for diagnosis and management of HE.
The most commonly used therapeutics to treat HE are lactulose and rifaximin. Researchers are also developing treatments that targets ammonia production and removal. For instance, AST-120 is under investigation and targets gut-derived toxins for liver cirrhosis. It can also be used to treat HE. The progression and development of HE sometimes depends on factors such as inflammation. This is compelling researchers to introduce various treatments that targets inflammation. Some of the most recent approaches to treat HE includes probiotics, albumin administration, and dialysis. Such emergence of novel hepatic encephalopathy treatment targets is identified as one of the key trends that will stimulate growth in the hepatic encephalopathy (HE) therapeutics market during the forecasted period.
In 2019, the market size of Hepatic Encephalopathy (HE) Therapeutics is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Hepatic Encephalopathy (HE) Therapeutics.
This report studies the global market size of Hepatic Encephalopathy (HE) Therapeutics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Hepatic Encephalopathy (HE) Therapeutics sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
ASKA Pharmaceutical
COSMO PHARMACEUTICALS
Mallinckrodt
Valeant
...
Market Segment by Product Type
Lactulose
Rifaximin
Neomycin
Probiotics
Thiamine
Market Segment by Application
Acute Liver Failure
Portal Systemic Bypass Without Liver Disease
Liver Cirrhosis
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Hepatic Encephalopathy (HE) Therapeutics status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Hepatic Encephalopathy (HE) Therapeutics manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Hepatic Encephalopathy (HE) Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Lactulose
- 1.3.3 Rifaximin
- 1.3.4 Neomycin
- 1.3.5 Probiotics
- 1.3.6 Thiamine
- 1.4 Market Segment by Application
- 1.4.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2019-2025)
- 1.4.2 Acute Liver Failure
- 1.4.3 Portal Systemic Bypass Without Liver Disease
- 1.4.4 Liver Cirrhosis
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size
- 2.1.1 Global Hepatic Encephalopathy (HE) Therapeutics Revenue 2014-2025
- 2.1.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales 2014-2025
- 2.2 Hepatic Encephalopathy (HE) Therapeutics Growth Rate by Regions
- 2.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales by Regions 2014-2019
- 2.2.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Hepatic Encephalopathy (HE) Therapeutics Sales by Manufacturers
- 3.1.1 Hepatic Encephalopathy (HE) Therapeutics Sales by Manufacturers 2014-2019
- 3.1.2 Hepatic Encephalopathy (HE) Therapeutics Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Hepatic Encephalopathy (HE) Therapeutics Revenue by Manufacturers (2014-2019)
- 3.2.2 Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Hepatic Encephalopathy (HE) Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.3 Hepatic Encephalopathy (HE) Therapeutics Price by Manufacturers
- 3.4 Key Manufacturers Hepatic Encephalopathy (HE) Therapeutics Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Hepatic Encephalopathy (HE) Therapeutics Market
- 3.6 Key Manufacturers Hepatic Encephalopathy (HE) Therapeutics Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Lactulose Sales and Revenue (2014-2019)
- 4.1.2 Rifaximin Sales and Revenue (2014-2019)
- 4.1.3 Neomycin Sales and Revenue (2014-2019)
- 4.1.4 Probiotics Sales and Revenue (2014-2019)
- 4.1.5 Thiamine Sales and Revenue (2014-2019)
- 4.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales Market Share by Type
- 4.3 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type
- 4.4 Hepatic Encephalopathy (HE) Therapeutics Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales by Application
6 United States
- 6.1 United States Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Company
- 6.2 United States Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Type
- 6.3 United States Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Application
7 European Union
- 7.1 European Union Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Company
- 7.2 European Union Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Type
- 7.3 European Union Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Application
8 China
- 8.1 China Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Company
- 8.2 China Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Type
- 8.3 China Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Company
- 9.2 Rest of World Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Type
- 9.3 Rest of World Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Application
- 9.4 Rest of World Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Countries
- 9.4.1 Rest of World Hepatic Encephalopathy (HE) Therapeutics Sales by Countries
- 9.4.2 Rest of World Hepatic Encephalopathy (HE) Therapeutics Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 ASKA Pharmaceutical
- 10.1.1 ASKA Pharmaceutical Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Hepatic Encephalopathy (HE) Therapeutics
- 10.1.4 Hepatic Encephalopathy (HE) Therapeutics Product Introduction
- 10.1.5 ASKA Pharmaceutical Recent Development
- 10.2 COSMO PHARMACEUTICALS
- 10.2.1 COSMO PHARMACEUTICALS Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Hepatic Encephalopathy (HE) Therapeutics
- 10.2.4 Hepatic Encephalopathy (HE) Therapeutics Product Introduction
- 10.2.5 COSMO PHARMACEUTICALS Recent Development
- 10.3 Mallinckrodt
- 10.3.1 Mallinckrodt Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Hepatic Encephalopathy (HE) Therapeutics
- 10.3.4 Hepatic Encephalopathy (HE) Therapeutics Product Introduction
- 10.3.5 Mallinckrodt Recent Development
- 10.4 Valeant
- 10.4.1 Valeant Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Hepatic Encephalopathy (HE) Therapeutics
- 10.4.4 Hepatic Encephalopathy (HE) Therapeutics Product Introduction
- 10.4.5 Valeant Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Hepatic Encephalopathy (HE) Therapeutics Sales Channels
- 11.2.2 Hepatic Encephalopathy (HE) Therapeutics Distributors
- 11.3 Hepatic Encephalopathy (HE) Therapeutics Customers
12 Market Forecast
- 12.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales and Revenue Forecast 2019-2025
- 12.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales Forecast by Type
- 12.3 Global Hepatic Encephalopathy (HE) Therapeutics Sales Forecast by Application
- 12.4 Hepatic Encephalopathy (HE) Therapeutics Forecast by Regions
- 12.4.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales Forecast by Regions 2019-2025
- 12.4.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Hepatic Encephalopathy (HE) Therapeutics . Industry analysis & Market Report on Hepatic Encephalopathy (HE) Therapeutics is a syndicated market report, published as Global (United States, European Union and China) Hepatic Encephalopathy (HE) Therapeutics Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Hepatic Encephalopathy (HE) Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
